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Deficient cytotoxic T cell function due to phar-macologic immunosuppression in transplanta-tion settings sensitizes these patients to post-
transplantation lymphoproliferative disorders (PTLD) 
which represent a heterogeneous group of pathologic 
lymphoid hyperplasia and lymphoid neoplasia1-3— a 
challenging complication of organ transplantation, which 
is usually fatal if untreated.4 Current evidence suggests 
that recipients of solid organ allograft are at a 25- to 
500-fold greater risk for developing PTLD within the 
first year after transplantation.5 The overall reported in-
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BACKGROUND AND OBJECTIVES: the presentation time of post-transplantation lymphoproliferative disorders 
(PtLD) are not well described because of the limited number of cases occurring at each center and lack of a 
reliable and unequivocal classification together with the absence of multi-institutional prospective studies. We 
gathered information on the histopathological and clinical features and prognosis of the disease in a very large 
number of heart and lung transplant recipients, with data from 27 previous reports, with an emphasis of time of 
presentation.
DESIGN AND SETTING: retrospective analysis of data for individual patients from published studies, entered 
into a database and reanalyzed.
METHODS: a comprehensive review of the literature by Pubmed and Google scholar was performed to find all 
data available reports on PtLD after heart and lung transplantation.  
RESULTS: Data from 288 PtLD patients after heart or lung transplantation from 27 reports were entered into 
analysis. heart and lung recipients with early-onset PtLD compared with late-onset PtLD were significantly 
more likely to be of the B cell type (100% vs. 89.8%, respectively; P=.05). PtLD in patients with early onset was 
less likely to involve the skin (P=.05) and spleen (P=.015), but more frequently complications of the respiratory 
tract (P=.002). morphology of PtLD lesions was significantly different between the two groups with a priority for 
late-onset PtLD to represent non-hodgkin lesions (P=.009). no difference was found between the two groups 
in survival (P=.237). one and five-year survival rates for early-onset PtLD patients were 65% and 46%, respec-
tively; compared to 53% and 41%, respectively, for the late-onset PtLD.
CONCLUSION: Due to a higher incidence of respiratory tract involvement in the early-onset PtLD patients and 
skin and spleen involvement in late-onset PtLD, we suggest that all heart/lung graft recipients should be evalu-
ated for potential multiorgan disease based early or late presentation. further multi-institutional prospective 
studies are needed to confirm our results.
cidence of PTLD is 1% to 20%6-9 but it depends on the 
type of allograft transplanted; the immunosuppression 
type and intensity; the occurrence of viral infections, 
particularly Epstein-Barr virus (EBV); underlying 
disease; and age.9,10 The prevalence of PTLD in heart 
and lung transplant recipients is supposed to be at least 
twice that of recipients of other transplant types and 
up to 9.4%,11,12 rising to 20% in pediatric series;13-18 this 
rate ranges from 1.7% to 9% in liver recipients.19-21
Time of the malignancy onset is one of the most 
relevant characteristics of the PTLD, which can pre-
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dict the behavior and features of the disease. Early 
onset (occurring within the first year post transplan-
tation) and late-occurring PTLD (developing more 
than one year after transplantation) each represent 
distinct pathological and prognostic characteristics; 
and therefore may have different risk factors. For ex-
ample, some authors have speculated that EBV-posi-
tive transplant patients represent early-onset PTLD 
than those with EBV negative serology;3,22 evidence 
suggests that EBV–positive PTLD usually develops 
within 24 months post transplantation in organ recipi-
ents, whereas their EBV-negative counterparts have a 
median onset around 50 to 60 months after transplan-
tation.2 Other investigators have suggested that EBV-
negative PTLD results in a worse prognosis compared 
with early-onset PTLD (the latter is more likely to 
present with EBV positive serology).23-26 Moreover, the 
type and intensity of immunomodulation have also been 
shown as interfering factors.27
PTLD generally manifests during the first post trans-
plantation year28-30 and can present as early as less than a 
month to as late as several decades after transplantation. 
Although the general concept is that early-onset PTLDs 
have a favorable outcome, late-onset PTLD is thought 
to behave more alike aggressive lymphoma. Late-onset 
PTLD represents a distinct clinicopathological subset 
occurring more frequently in older patients with long 
latency period, often displays EBV negativity, responds 
poorly to treatment and has worse prognosis.31 In our 
previous studies, we studied early- and late-onset PTLD 
in renal and liver transplant recipients.17,18,22 The limited 
number of cases occurring at each center and lack of a 
reliable and unequivocal classification together with the 
absence of multi-institutional prospective studies makes 
it hard to have a reliable view of the different character-
istics of the disease so as to develop preventive as well as 
treatment strategies. The present study, however, deals 
with different aspects of PTLD, including histopatho-
logical and clinical features and prognosis of the disease 
in a very large number of heart and lung transplant re-
cipients, whose data were obtained from 27 previous 
reports, particularly with regard to presentation time 
(early vs late onset).
METHODS
We conducted a comprehensive search for the available 
data by PubMed and Google Scholar search engines 
for reports of lymphoproliferative disorders occurring 
in heart and lung transplant patients with regard to 
the disease presentation time. Keywords used for this 
purpose were “lymphoproliferative disorders + trans-
plantation + heart + early onset” “lymphoproliferative 
disorders + transplantation + heart + late onset” “lym-
phoproliferative disorders + heart transplantation + 
presentation time” “lymphoproliferative disorder + 
transplantation + heart + time to PTLD” “PTLD 
+ heart + early onset” “PTLD + heart + late onset” 
“lymphoproliferative disorders + transplantation + 
lung + early onset” “lymphoproliferative disorders + 
transplantation + lung + late onset” “lymphoprolifera-
tive disorders + lung transplantation + presentation 
time” “lymphoproliferative disorder + transplantation 
+ lung + time to PTLD” “PTLD + lung + early onset” 
“PTLD + lung + late onset”. In cases where we were 
unable to achieve the full text of the articles, emails 
were sent to correspondent authors requesting the ar-
ticle. We only included studies in which the data for 
each patient was presented separately, which was then 
entered data into a database; studies without data for 
each individual patient were excluded from analysis. 
To minimize selection bias, we only included stud-
ies reporting series of patients from single or multi-
center populations. Studies with any specific selection 
criterion were excluded from the analysis; moreover, 
only studies that had patients with early- and late-on-
set PTLD were included in this analysis. A standard 
questionnaire was developed to collect data from dif-
ferent published studies. Finally, data from 27 previ-
ously published studies from various countries23,32-57 
were included in the study. The time between trans-
plantation and PTLD onset was defined as the period 
between the graft and the first signs of PTLD or diag-
nosis, depending on definitions in individual studies. 
Patients who presented with PTLD within the first 12 
months post transplantation were considered as “ear-
ly-onset PTLD” group, and heart and lung graft re-
cipients who represented with the disease beyond this 
time period after transplantation were categorized as 
“late onset PTLD” patients.
Study population
Recipients of heart and/or lung grafts who developed 
PTLD through their treatment course were included 
in the analysis. Patient status regarding EBV infection 
was documented in 158 (54.9%) patients, of whom 
114 (72.2%) were reported positive. Because data used 
for this study was from different studies with differ-
ent methodologies, we were not able to get all data we 
needed from all the included patients. Disseminated 
lymphoma was diagnosed when it was declared by 
the authors or at least three different organs (different 
lymph node areas were excluded from analysis due to 
lack of knowledge on how to categorize) were involved 
by PTLD, as reported in 35 (21.5%; 125 missing data) 
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patients. Multiorgan involvement defined as involve-
ment of more than a unique organ as well as more than 
one lymphatic region was available in 78 (37.7%; 81 
missing data) patients. 
At lymphoma diagnosis, all patients were receiving 
and had received immunosuppressive regimens consist-
ing of varying combinations of azathioprine, prednisone, 
cyclosporine, mycophenolate mofetil, and antithymo-
cyte/lymphocyte globulin (ATG/ALG) and OKT3. A 
rather uniform approach was used to manage all PTLD 
patients in the included reports. On diagnosis of PTLDs, 
the first step in almost all reports was to decrease or dis-
continue immunosuppressive therapy; different regimens 
of chemotherapy with or without surgical interventions 
were also used for some of patients. 
Response to treatment
Response to treatment was defined as any favorable 
change in the cancer measures as well as clinical condition; 
data on PTLD response to treatment was reported by 
authors for only 49 (17%) patients, of whom 28 (57.1%) 
patients responded to anti-lymphoma therapy. However, 
we developed new criteria for defining remission rates for 
the study population. While the remission episode was 
defined when patients were alive after their 24th month 
of PTLD diagnosis (since all reported cases having this 
criterion had at least one confirmed remission episode) 
and no remission was defined when a patient died within 
the first month post-PTLD diagnosis (because among 
reported cases there were no patients who died at the 
first post-transplant month who were reported to have 
any remission episodes). According to this criteria, 143 
(49.7%) patients represented data on remission of whom 
95 (66.4%) had at least one response to treatment, irre-
spective of their future disease course. Overall mortality 
was 110 (38.2% of the study population and 58.2% of the 
reported cases; 99 patients had missing data) patients; 
death due to PTLD was defined if authors stated the 
fact, when patient died within 6 months post diagnosis, 
or when patients died due to PTLD treatment complica-
tions. Overall, 79 (41.8% of the reported data; 71.8% of 
the whole mortality rate) patients died due to the disease 
based on the abovementioned criteria. 
Statistical analysis
Software used for data analyses was SPSS v.13.0. 
Statistical differences between patients’ subgroups were 
performed by using chi-square and Fisher exact tests for 
proportions and the t test for continuous data. Survival 
analysis was done with life tables and Kaplan-Meier 
methods and log-rank test. All statistical tests were per-
formed at the 0.05 significance level.
RESULTS
Overall, 288 patients with lymphoproliferative disor-
ders after heart or lung transplantation were entered 
into the analysis. There were 180 (62.5%) heart trans-
plant subjects and 108 (37.5%) lung graft recipients. 
Gender make up composed of 126 (68.9%) males and 
57 (31.1%) female patients (missing data on 105). 
Mean (standard deviation) age at diagnosis of PTLD 
was 35.6 (22.6) years. The mean interval between 
transplantation and the diagnosis of PTLD was 40.8 
(38.7) months whereas follow up time after diagnosis 
of PTLD was 25.0 (35.0) months. 
Characteristics by onset time are summarized in 
Table 1. Heart and lung recipients with early onset 
PTLD were significantly more likely to be of the B cell 
type (100% vs. 89.8%, respectively; P=.05). Heart/lung 
transplant recipients with early-onset PTLD were com-
parable to their counterparts with late-onset disease as 
to rate of EBV infection rate (P=.2), total mortality rate 
(P=1.0), death due to PTLD (according to the defined 
criteria described in the methods section; P=.718), 
multiorgan involvement (according to the defined cri-
teria; P=.645), disseminated PTLD (according to the 
defined criteria; P=.225). Gender make up was also dif-
ferent between the two patient groups with a trend to-
ward a male predominance for late-onset PTLD (76% 
vs. 58%, respectively; P=.015). Heart/lung transplant 
patients with early-onset PTLD more frequently had 
remission episodes in their disease course (P=.041) 
and they also were more likely to be taking mycophe-
nolate mofetil-based immunosuppression (vs. azathio-
prine based; P=.033). 
Heart/lung transplant patients with early- or late-
onset PTLD were comparable in age the time of trans-
plantation (median age 42.0 versus 41.0 years; P=.763). 
Histopathological evaluations with regard to both the 
clonality (P=1.0) of specimen achieved from PTLD le-
sions in heart/lung transplant recipients showed com-
parable results in early- and late-onset PTLD patients; 
however, morphology of PTLD lesions was significant-
ly different between the two groups, with more late-
onset PTLD representing non-Hodgkin lesions (49% 
vs. 26%, respectively, P=.009). PTLD in patients with 
early onset was less likely to involve skin (P=.05) and 
spleen (P=.015) but more frequently in complications 
of the respiratory tract (P=.002) (Table 2). 
At the last follow, 110 (58.2%) patients were dead 
(with 99 missing data). When death (irrespective of 
the reason) was used as the final outcome, the log-rank 
test showed no differences between the two groups in 
survival (P=.237; Figure 1); moreover, no statistically 
significant difference was seen between the two groups 
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when death only due to PTLD was used as the final 
outcome (based on the defined criteria in the methods 
section; P=.405). Separate reanalysis of data regarding 
basis of immunosuppression also did not show any sur-
vival preferences for any of the groups (P>0.4). One and 
five-year survival rates for early onset PTLD patients 
were 65% and 46%, respectively; compared to 53% and 
41%, respectively, for the late onset PTLD.
DISCUSSION
Lymphoid tumors were first reported in organ trans-
plant recipients in 1969 by Penn et al58 and they are 
frequently termed as PTLD. PTLD are significant 
complications in solid organ transplant recipients 
with a broad range of clinical findings from self lim-
ited mononucleosis-type syndrome to rapidly progres-
sive and disseminated disease.59 PTLD commonly 
represents with uncontrolled B-cell proliferation with 
histopathologic features that range from plasmacytic 
hyperplasia to monomorphic large cell non-Hodgkin 
lymphomas. The reported incidence of the PTLD var-
ies widely depending on the organ transplanted,4, 60-65 
with the highest incidence in the recipients of small 
bowel and heart and lung, viral infections and potency 
and length of immunosuppressive therapy.62,64 Upon 
the introduction of highly potent immunosuppressive 
agents aiming at the prevention of graft rejection, the 
frequency of PTLD has dramatically increased62 and 
the time interval between transplantation and the on-
set of PTLD has decreased.62 
The highest reported rates of lymphomas were 
among graft recipients within the first 12 months post 
transplantation, so called early-onset PTLD with a 
slowly decreasing incidence rate over time.66 In our se-
ries, 37% (106 patients) were early-onset PTLD and 
the remaining patients developed the disease beyond 
the first post transplant year. Nevertheless, we were not 
able to estimate the incidence of the PTLD after heart 
and lung transplantation because of methodological 
limitations: the first reason being the inclusion criteria, 
which excluded some studies from analysis; the second 
reason being that the existing literature does not rep-
resent the whole or even a comparable sample of the 
PTLD patients, because the literature does not include 
reports from all centers of the world. 
The behavior and histopathological features of late-
onset PTLD have been previously reported by different 
authors;18,67,68 most of them focused on renal transplant 
recipients. The patients were older with lymphomas of 
the monomorph type with few responses to therapy. In 
our previous studies, we reported our findings on ear-
ly- and late-onset PTLD in renal and liver transplant 
recipients;17,18,22 in those studies, we also found that 
PTLD patients, despite all treatment strategies, had a 
high mortality rate. 
In our study on heart and lung transplant recipients, 
we also found that histopathological features of PTLD 
have a trend toward the monomorph lesions in late-on-
set disease, but no difference in patient age regarding 
their PTLD onset time was found. Both of the above-
mentioned findings were consistent with our previous 
study on liver transplant PTLD patients. On the other 
hand, we found that heart/lung transplant recipients 
who represent PTLD beyond the first year post-trans-
plantation are more likely to be male; this finding con-
trasts with our study on liver transplant PTLD in which 
late onset disease was more frequently seen in females. 
The PTLD presentation time is of particular inter-
est as many authors believe that the time between graft 
and PTLD onset could be the main prognostic factor 
as well as the most important parameter to use in se-
lecting therapeutic options.8,68,69 In the current study, 
Table 1. Characteristics of heart and lung transplant recipients with early and late onset 
post-transplant lymphoproliferative disorder.
Variables Early onset 
Late 
onset P
Available 
data
mean age 
(standard deviation) (y) 6.1 (21.9) 5.2 (2.1) .76 279
Pediatric (<18 y) 28 (27.2) 54 (0.7) .587 279
gender male 45 (58.4) 81 (76.4) .015 18
mean (Sd) time to PTLd 
development (mo) 6. (.2) 60.9 (5.6) 288
multiorgan involvement* 2 (4.8) 55 (9.0) .645 207
disseminated PTLd* 8 (15.4) 27(24.) .225 16
morphology .01 168
   early lesion (plasmacytic 
   hyperplasia) 2 (.2) 14 (1.)
   Polymorphic B cell 
   lymphoma 26 (41.) 21 (20.0)
   monomorphic PTLd 4 (54.0) 68 (64.8)
   Hodgkin lymphoma 1 (1.6) 2 (1.9)
eBV status 44 (78.6) 70 (68.6) .199 158
remission episode 11 (22.0) 7 (9.8) .041 14
monoclonal lesions vs. 
polyclonal 15 (78.9) 7 (80.4) 1.0 65
Lymphoma cell type B cell 9 (100) 79 (89.8) .05 127
use of induction therapy 1(25) 16 (72.7) .104 26
*according to the criteria defined in the methods section; 
data are n (%) or mean (standard deviation)
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we found no difference in the survival of patients with 
early- or late-onset PTLD. This finding differs from 
previous reports which suggest a superior outcome for 
early-onset PTLD in their centers but in concordance 
with our previous report on liver transplant patients.22 
Figure 1 might give the appearance that in the first years 
post transplantation, early-onset PTLD has a relatively 
higher survival, but reanalysis of the data did not show 
any significant difference.
Using the Collaborative Transplant Study database, 
investigators have found that treatment with ATG/
ALG or OKT3 increased the risk of lymphoma only 
during the first year after transplantation, whereas the 
risk was similar to that in non-antibody-treated pa-
tients in subsequent years.24 However, in the present 
study, presentation time of PTLD did not differ with 
regard to induction therapy. 
It is generally accepted that immunosuppressive 
therapy favors both EBV infection (either primary or 
reactivation of latent infection) and growth and trans-
formation of EBV-infected B-cells in an impaired 
cytotoxic T-cell function era. Previous studies have 
found several EBV-negative patients with late-onset 
PTLD.6,69,70 In this study, however, we found no sig-
nificant difference between early- and late-onset PTLD 
regarding EBV infection rates, which contrasts with 
our previous study on liver transplant PTLD subjects 
where we found a highly significant reduced EBV posi-
tive rates for late-onset PTLD compared to those with 
early-onset disease. 
In our previous study on late-onset PTLD in re-
nal allograft recipients, the major sites of PTLD were 
gastrointestinal tract and peripheral lymph nodes.17 
Another study of ours on early-onset PTLD in renal 
recipients, we found an allograft involvement preferen-
tial with 25% of the whole study population.18 In an-
other study on liver recipients, we however found that 
late-onset PTLD is more likely to involve colon and 
genitalia (the latter did not reach significance level), 
while early-onset PTLD more frequently complicates 
liver grafts. In the current study, however, we observed 
that the skin and spleen are the two preferred involve-
ment organs in the late-onset PTLD whilst the respira-
tory tract is more frequently complicated by early onset 
disease in the heart/lung transplant recipients.
Potential criticisms of our study are, first, that our 
study population was gathered from different reports 
with inconsistent methodologies. We also believe that 
this is the unique major limitation for this study leading 
to substantial missing data for some of study variables 
and thus, decreasing the power of our analyses. This limi-
tation was most prominent for special data that are not 
Table 2. Frequency of involved organs in 168 heart and lung 
transplant recipients with early or late onset PTLd.
Involved organs Early onset Late onset Sig.
Orbital 0 4(2.4) 0.11
Skin 0 8(4.9) 0.05
Stomach 1 (1.) 6 (.7) 0.47
genitalia 1 (1.) (1.8) 1.0
CnS  4 (5.)  (1.8) 0.212
Skeleton 0 2 (1.2) 1.0
Spleen 1 (1.) 16 (9.8) 0.015
Colon 5(6.6) 6(.7) 0.1
Small intestine (.9) 16(9.8) 0.197
renal involvement 1(1.) 7(4.) 0.441
Liver involvement 5(6.6) 15(9.1) 0.620
respiratory system 25(2.9) 24(14.6) 0.002
Bone marrow 2(2.6) 16(9.80) 0.06
1.0
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Figure 1. Survival curves of heart and lung transplant recipients with early and late 
onset disease.
original research reportPTLd Time OF OnSeT
Hematol Oncol Stem Cell Ther 4(1)     First Quarter 2011 hemoncstem.edmgr.com 15
typically included in reports on PTLD patients. Another 
limitation might be due to the inconsistencies between 
studies because results were not presented in the same 
way. For example, response to treatment was presented 
very dissimilarly in different studies; while in one study 
partial and complete remission was used to translate 
the results, in another only “response to treatment” was 
used and in some others no specific terminology was em-
ployed. So we ought to invent new methods to accumu-
late the existing data for analysis. 
In conclusion, we found that heart/lung transplant 
patients who develop PTLD have comparable patient 
outcomes both in the early and late onset disease. Due 
to a higher incidence of respiratory tract involvement 
in the early onset PTLD patients and skin and spleen 
involvement in late onset PTLD, authors suggest that 
all heart/lung graft recipients should receive enough 
evaluations for a potential multi organ disease regard-
ing their presentation time. Further multi-institutional 
prospective studies are needed to confirm our results.
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